Dr Patrick Blin (MD-Msc) specializes in Public Health, Biostatistics and Pharmaco-epidemiology, with more than 30 years of scientific leadership experience in epidemiology and pharmaco-epidemiology. Its main area of interest is the evaluation of the performance of drugs in real life for European and national Post-Approval Studies and Risk-Management Plans, and since 2003 using the nationwide French Claims database. He specialized in the application of high-dimensional propensity scores for the comparison of risk-benefit using the SNDS nationwide French Claims database.
He was born in Paris (France) and did his medical studies at the Bicêtre Faculty of Medicine of Paris-Saclay University. He then completed the Master of Biomathématiques of Pr Alain-Jacques Valleron (Member of the Académie des Sciences). After a year in an inter-African public health organization, he participated for 3 years in the creation of a new hospital-university department of biostatistics in Paris (Pr Claude Chastan), then headed for 3 years Biostatistics department in the pharmaceutical industry, and became for many years the scientific director of CRO specialized in epidemiology and pharmaco-epidemiology.
He has been working with the Bordeaux team since the early 1990s, and joined BPE full-time in 2012 to become its Medical-Scientific Director. He has been appointed by decree member of the Expert Committee for Health Research, Studies and Evaluations (CEREES), then to the Ethics and Scientific Committee for Health Research, Studies and Evaluations (CESREES), of which he is Vice-President since the beginning. He is also a member of the National Commission for Research Involving Humans (CNRIPH).
Dr Patrick Blin has participated in the scientific committee of numerous epidemiology and pharmaco-epidemiology congress, and He has co-authored over 120 papers in peer-reviewed journals.